Holobiome, Inc.

Boston, MA · Founded 2015 · Biotech · Private

Probiotic therapeutic comprised of 2-3 human gut-derived bacterial strains engineered to enhance serotonin production and reduce inflammation for constipation treatment

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · holobiome.org

Sector: Biotech
Headquarters: Boston, MA
Founded: 2015
Latest Form D: $6.6M, Mar 2024
Total capital: $10.1M

Federal grants: $2.6M; 4 awards · 2019–2021; Rank in peer group#405 of 514
Private capital raised: $7.5M; 3 Form D · last Mar 2024; 31 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 2; 10 pending · first 2021; Rank in peer group#142 of 514

Capital timeline

Latest events

Mar 2024Private capital raisedForm D · SEC · 3rd filing$6.6M
Jul 2021Federal grantHealth and Human S · Phase I · Development of a therapeutic bacterial consortium for constipation$300K
Jun 2021Federal grantHealth and Human S · Phase II · Development of therapeutic GABA-producing bacteria$668K
Feb 2021Private capital raisedForm D · SEC · 2nd filing$300K
Jun 2020Federal grantHealth and Human S · Phase II · Development of therapeutic GABA-producing bacteria$1.3M
May 2019Federal grantHealth and Human S · Phase II · Development of therapeutic GABA-producing bacteria$300K
Dec 2018Private capital raisedForm D · SEC · 1st filing$625K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grantsBelow median
Granted patents#142 · top 28%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Philip StrandwitzResearcherExecutive Officer, DirectorLinked by 2 patents · $1.6M in grants as PI
Iain ChessellDirectorNamed in SEC Form D filings
Ian ChessellDirectorNamed in SEC Form D filings
Joan LaRovereDirectorNamed in SEC Form D filings
Kim LewisDirectorNamed in SEC Form D filings
Michael LafleurDirectorNamed in SEC Form D filings

Show all 7 people

Phil StrandwitzExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 12

Jan 1, 2026PendingModulation Of The Gut Microbiome To Treat Mental Disorders Or Diseases Of The Central Nervous SystemUSPTOApplication 19267001
Aug 26, 2025GrantedModulation Of The Gut Microbiome To Treat Mental Disorders Or Diseases Of The Central Nervous SystemUSPTOUS 12,397,022
Aug 21, 2025PendingTherapeutic Compositions And Methods Of Using Serotonin Modulating Microbiome-based Interventions To Treat Serotonin-related Diseases Or DisordersUSPTOApplication 18816824

Show all 12 patent records

Modulation Of The Gut Microbiome To Treat Mental Disorders Or Diseases Of The Central Nervous SystemJan 1, 2026 · Application 19267001Pending
Modulation Of The Gut Microbiome To Treat Mental Disorders Or Diseases Of The Central Nervous SystemAug 26, 2025 · US 12,397,022Granted
Therapeutic Compositions And Methods Of Using Serotonin Modulating Microbiome-based Interventions To Treat Serotonin-related Diseases Or DisordersAug 21, 2025 · Application 18816824Pending
Therapeutic Compositions And Methods Of Using Serotonin Modulating Microbiome-based Interventions To Treat Serotonin-related Diseases Or DisordersNov 24, 2022 · Application 17621767Pending
Methods And Compositions For Treating And Preventing Central Nervous System Disorders And Other Conditions Caused By Gut Microbial DysbiosisMar 31, 2022 · Application 17426178Pending
Modulation Of The Gut Microbiome To Treat Mental Disorders Or Diseases Of The Central Nervous SystemSep 14, 2021 · US 11,116,804Granted
Modulation Of The Gut Microbiome To Treat Mental Disorders Or Diseases Of The Central Nervous SystemApplication 62307991Pending
Prebiotic CombinationsApplication PCTUS2025017580Pending
Therapeutic Compositions And Methods Of Using Serotonin Modulating Microbiome-based Interventions To Treat Serotonin-related Diseases Or DisordersApplication PCTUS2020039947Pending
Methods And Compositions For Treating And Preventing Central Nervous System Disorders And Other Conditions Caused By Gut Microbial DysbiosisApplication PCTUS2020015728Pending
Modulation Of The Gut Microbiome To Treat Mental Disorders Or Diseases Of The Central Nervous SystemApplication PCTUS2017022091Pending
Inactivated Bacteroides Bacteria And Methods Of Use ThereofApplication PCTUS2025045084Pending

Palvella Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
XYLOCOR THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
Tracon Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
KHLORIS BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
PSY THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
MindImmune Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.